Will you offer adjuvant T-DM1 for patients with HER2+ breast cancer who have residual invasive disease following neoadjuvant therapy?

The KATHERINE trial was presented at this years San Antonio Breast Cancer Symposium and published on line in the NEJM Dec 5. The trial was a phase III randomized trial for women who residual disease post-neoadjuvant HER2-targeted chemotherapy regimens. The randomization was to 1:1 with either trastuzumab (control arm) or trastuzumab emtansine (TDM-1, experiment arm) for 14 cycles. A total 1486 women were randomized. At 3 years, the women free of invasive disease were 88% and 77%, in TDM-1 and tr...

Yes, I would argue that the KATHERINE trial data results in a treatment paradigm shift and that T-DM1 is the standard of care in patients with residual disease after neoadjuvant chemotherapy plus HER2-directed therapy. The results were reported at the 2018 San Antonio Breast Cancer Symposium and published in the New England Journal of Medicine. In this study, nearly 1,500 patients were randomized 1:1 to trastuzumab vs. T-DM1 for 14 cycles. Patients could have residual disease in the breast or ax...

Yes, I will. The Katherine trial showed an 11.3% improvement in invasive disease free survival at 3 years for patients rdceiving T-DM1 instead of trastuzumab after neoadjuvant therapy with chemo + anti-HER-2 agents.